Literature DB >> 22167256

Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency.

J H Boone1, M Goodykoontz, S J Rhodes, K Price, J Smith, K N Gearhart, R J Carman, T M Kerkering, T D Wilkins, D M Lyerly.   

Abstract

We evaluated Clostridium difficile prevalence rates in 2,807 clinically indicated stool specimens stratified by inpatient (IP), nursing home patient (NH), outpatient (OP), age, gender, and specimen consistency using bacterial culture, toxin detection, and polymerase chain reaction (PCR) ribotyping. Rates were determined based on the detection of toxigenic C. difficile isolates. We identified significant differences in the rates between patient populations and with age. Specimens from NH had a higher rate (46%) for toxigenic C. difficile than specimens from IP (18%) and OP (17%). There were no gender-related differences in the rates. Liquid specimens had a lower rate (15%) than partially formed and soft specimens (25%) and formed specimens (18%) for the isolation of toxigenic C. difficile. The nontoxigenic rate was lowest for NH (4%) and highest for patients<20 years of age (23%). We identified 31 different toxigenic ribotypes from a sampling of 190 isolates that showed the lowest diversity in NH. Fluoroquinolone resistance was observed in 93% of the 027 isolates, all of the 053 isolates, and in four other ribotypes. We observed different rates for toxigenic C. difficile in stratified patient populations, with the highest rate for NH, a low overall nontoxigenic rate, and fluoroquinolone resistance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22167256     DOI: 10.1007/s10096-011-1477-6

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  31 in total

1.  Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec.

Authors:  Jacques Pépin; Louis Valiquette; Benoit Cossette
Journal:  CMAJ       Date:  2005-09-22       Impact factor: 8.262

2.  Incidence of Clostridium difficile infection in inflammatory bowel disease.

Authors:  Joseph F Rodemann; Erik R Dubberke; Kimberly A Reske; Da Hea Seo; Christian D Stone
Journal:  Clin Gastroenterol Hepatol       Date:  2007-03       Impact factor: 11.382

3.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

Authors:  Sandra Dial; J A C Delaney; Alan N Barkun; Samy Suissa
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

4.  A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes.

Authors:  M Catherine McEllistrem; Robert J Carman; Dale N Gerding; C W Genheimer; L Zheng
Journal:  Clin Infect Dis       Date:  2004-12-15       Impact factor: 9.079

5.  Type-specific risk factors and outcome in an outbreak with 2 different Clostridium difficile types simultaneously in 1 hospital.

Authors:  A Goorhuis; S B Debast; J C Dutilh; C M van Kinschot; C Harmanus; S C Cannegieter; E C Hagen; E J Kuijper
Journal:  Clin Infect Dis       Date:  2011-09-13       Impact factor: 9.079

6.  Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan.

Authors:  Yi-Chun Lin; Yu-Tsung Huang; Pei-Jane Tsai; Tai-Fen Lee; Nan-Yao Lee; Chun-Hsing Liao; Shyr-Yi Lin; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

7.  Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents.

Authors:  Michelle M Riggs; Ajay K Sethi; Trina F Zabarsky; Elizabeth C Eckstein; Robin L P Jump; Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2007-09-04       Impact factor: 9.079

8.  Comparison of BD GeneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection.

Authors:  Elizabeth J Kvach; David Ferguson; Paul F Riska; Marie L Landry
Journal:  J Clin Microbiol       Date:  2009-10-28       Impact factor: 5.948

Review 9.  Clostridium difficile and inflammatory bowel disease.

Authors:  Mazen Issa; Ashwin N Ananthakrishnan; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2008-10       Impact factor: 5.325

10.  The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission.

Authors:  Evelyn M Clayton; Mary C Rea; Fergus Shanahan; Eamonn M M Quigley; Barry Kiely; Colin Hill; R Paul Ross
Journal:  Am J Gastroenterol       Date:  2009-03-24       Impact factor: 10.864

View more
  14 in total

1.  Is fidaxomicin worth the cost? An economic analysis.

Authors:  Sarah M Bartsch; Craig A Umscheid; Neil Fishman; Bruce Y Lee
Journal:  Clin Infect Dis       Date:  2013-05-23       Impact factor: 9.079

2.  Real-time cellular analysis coupled with a specimen enrichment accurately detects and quantifies Clostridium difficile toxins in stool.

Authors:  Bin Huang; Dazhi Jin; Jing Zhang; Janet Y Sun; Xiaobo Wang; Jeffrey Stiles; Xiao Xu; Mini Kamboj; N Esther Babady; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

Review 3.  A clinical and epidemiological review of non-toxigenic Clostridium difficile.

Authors:  Mukil Natarajan; Seth T Walk; Vincent B Young; David M Aronoff
Journal:  Anaerobe       Date:  2013-05-29       Impact factor: 3.331

4.  Impact of Clostridium difficile infection among pneumonia and urinary tract infection hospitalizations: an analysis of the Nationwide Inpatient Sample.

Authors:  Monideepa B Becerra; Benjamin J Becerra; Jim E Banta; Nasia Safdar
Journal:  BMC Infect Dis       Date:  2015-07-01       Impact factor: 3.090

5.  Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality.

Authors:  J H Boone; L R Archbald-Pannone; K N Wickham; R J Carman; R L Guerrant; C T Franck; D M Lyerly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-22       Impact factor: 3.267

6.  Clostridium difficile carriage in hospitalized cancer patients: a prospective investigation in eastern China.

Authors:  Wei-Jia Fang; Da-Zhi Jing; Yun Luo; Cai-Yun Fu; Peng Zhao; Jiong Qian; Bing-Ru Tian; Xiao-Gang Chen; Yu-Long Zheng; Yi Zheng; Jing Deng; Wei-Hua Zou; Xue-Ren Feng; Fan-Long Liu; Xiao-Zhou Mou; Shu-Sen Zheng
Journal:  BMC Infect Dis       Date:  2014-09-29       Impact factor: 3.090

7.  Learning Data-Driven Patient Risk Stratification Models for Clostridium difficile.

Authors:  Jenna Wiens; Wayne N Campbell; Ella S Franklin; John V Guttag; Eric Horvitz
Journal:  Open Forum Infect Dis       Date:  2014-07-15       Impact factor: 3.835

8.  Recurrence and death after Clostridium difficile infection: gender-dependant influence of proton pump inhibitor therapy.

Authors:  Ophélie Dos Santos-Schaller; Sandrine Boisset; Arnaud Seigneurin; Olivier Epaulard
Journal:  Springerplus       Date:  2016-04-11

Review 9.  Reducing inappropriate antibiotic prescribing in the residential care setting: current perspectives.

Authors:  Ching Jou Lim; David C M Kong; Rhonda L Stuart
Journal:  Clin Interv Aging       Date:  2014-01-13       Impact factor: 4.458

10.  Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection.

Authors:  J H Boone; J R DiPersio; M J Tan; S-J Salstrom; K N Wickham; R J Carman; H R Totty; R E Albert; D M Lyerly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-06-18       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.